Related Experiment Video
Updated: Jun 23, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Evolution of raltegravir resistance during therapy
Nadine Sichtig1, Saleta Sierra, Rolf Kaiser
1Institute of Virology, University of Cologne, Germany.
The Journal of Antimicrobial Chemotherapy
|May 19, 2009
Summary
Raltegravir resistance mutations did not appear at baseline in HIV-1 subtypes. During therapy, resistance mutations evolved, influenced by HIV-1 subtype and raltegravir exposure duration.
Area of Science:
- Virology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Raltegravir is a key integrase inhibitor for HIV-1 treatment.
- Understanding resistance mutation dynamics is crucial for optimizing therapy.
- HIV-1 subtypes may influence resistance development.
Purpose of the Study:
- To determine the prevalence of raltegravir resistance mutations at baseline.
- To track the evolution of these mutations during raltegravir therapy.
- To investigate the impact of HIV-1 subtypes on resistance patterns.
Main Methods:
- Sequencing of the integrase gene from plasma samples of HIV-1 infected patients (subtype B and non-B).
- Analysis of baseline genotypes for resistance mutations.
- Monitoring of resistance evolution in patients undergoing raltegravir therapy.
Main Results:
- No primary raltegravir resistance mutations were detected at baseline.
- Secondary mutations (L74M, T97A, V151I, G163R) were found at low frequencies (<4%).
- Primary mutations (N155H, Q148R/H, Q143R) emerged during therapy, with Q148R/H specific to subtype B. Mutation prevalence varied with therapy duration.
Conclusions:
- Baseline genotypes showed secondary mutations, but not primary resistance mutations.
- Raltegravir resistance mutations developed during therapy when viral suppression was suboptimal.
- The emergence of resistance was dependent on HIV-1 subtype and duration of raltegravir treatment.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
00:36Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...